SVF Regenerative Therapy: MICROLYZER Kit Cleared for Orthopedics in Boao Lecheng

Public reports from Boao Lecheng post says Hainan Boao Luyi Hospital introduced MICROLYZER intelligent SVF (stromal vascular fraction) regenerative therapy, approved by the Lecheng pilot-zone Medical Products Administration for clinical use in orthopedics—targeting bone/joint tissue injury, tendon/ligament injury, and muscle injury as an “international autologous regenerative repair” option. Points below are source claims. Confirm indication, license, and price in writing. Not medical advice.

Approval summary (as stated)

The post shows Hainan Provincial MPA paperwork (琼药监械〔2021〕234, seal dated 22 Jan 2021) and summarizes: Lecheng’s Medical Products Administration approved clinical use at Luyi Hospital Orthopedics of the MICROLYZER SMART SVF KIT for preparing autologous adipose SVF; delivery via intra-articular injection to aid repair of damaged joints, ligaments, and muscle; preparation and use must follow pilot-zone biomedical-technology rules.

Traditional-care gaps (as stated)

Cartilage, tendons/ligaments, and skeletal muscle heal poorly. For degenerative OA: drugs, steroids, and hyaluronate mainly short-term relief; replacement is invasive and riskier with comorbidities. Tendons/ligaments: poor blood supply, slow healing, fibrosis, re-tear. Muscle: fibrosis, fat infiltration, strength loss after chronic tears—rehab/surgery rarely reverse atrophy.

Core pain point in the post: traditional plans focus on symptom relief and struggle to deliver structural regeneration and functional rebuild of damaged tissue.

Claimed SVF value

SVF is framed as an autologous fat–derived “repair cell set” including MSCs, endothelial progenitors, pericytes, M2 macrophages, and Tregs—working on anti-inflammation, analgesia, angiogenesis, anti-fibrosis, and regeneration (anti-inflam → pain relief → regen → function). Marketing language from the source.

MICROLYZER claims (source figures)

Enzyme-free mechanical separation (physical emulsification + four-stage filtration; no collagenase). Closed Luer-lock workflow from harvest to SVF; ISO13485 and CE; >5,300 kits globally with no recorded serious adverse events in the post. Viability ≥90%; ~2×10⁷ nucleated cells/mL concentrate; high CD73/CD90; standardized bedside extract–prepare–inject for outpatient/day surgery.

For joint injury / degenerative OA the post claims joint protection, cartilage repair, and delay/avoidance of replacement; VAS pain −40%–60%, ongoing WOMAC gains, stable effect 1–2+ years; minimally invasive, no hospital stay, suitable for elderly/multimorbid patients; ESSKA Grade A recommendation. Treat numbers as source claims only.

Tendon, muscle, and who is listed

Tendons/ligaments: collagen remodeling; claimed better/faster than PRP with lower re-tear. Muscle: ~40% less fibrosis, fiber regen, less fat infiltration/atrophy. Listed groups: OA/joint injury unwilling or unfit for replacement; chronic tendinitis/ligament injury; strain with fibrosis/stiffness; failed meds/PT/PRP; preference for minimally invasive tissue-sparing care—individual hospital assessment required.

Background in the post: developed by Turkey’s T-LAB, EU CE, exported to 70+ countries; ESSKA Grade A; highlighted by CMA orthopedics/sports-medicine branches; special access in Lecheng with Luyi Hospital as China’s first clinical site. It claims to fill a domestic gap in regenerative repair for degenerative joints, tendons, and muscle. Confirm license validity, indication, and a written estimate before travel.

The Boao Lecheng International Medical Tourism Pilot Zone, approved by the State Council in February 2013, pilots franchised medical care and health management—aiming for “three synchronizations” of technology, equipment, and drugs with international standards.